IVONESCIMAB for Recurrent and/or metastatic squamous cell carcinoma of the head and neck

Inclusion criteria

• {"criterion_text":"- Patient capable of voluntary giving her/his written informed consent.\n- Adequate organ function determined by the following requirements: a.\tHaematology (satisfactory laboratory test results obtained during the screening period, and no blood components used within 14 days of cell growth factor supportive therapy): i.\tAbsolute neutrophil value (ANC) ≥ 1.5×109/L (1,500/mm3) ii.\tPlatelet count ≥ 100×109/L (100,000/mm3) iii.\tHaemoglobin ≥ 10 g/dL b.\tKidneys: i.\tCalculated creatinine clearance ≥ 50 mL/min ii.\tUrine protein ≤ 2+ or 24 hours (h) urine protein quantification < 1.0 g c.\tLiver: i.\tSerum total bilirubin ≤ 1.5× upper limit of normal (ULN); for patients with liver metastases or confirmed/suspected Gilbert syndrome, ≤ 3 × ULN ii.\tAST and ALT ≤ 2.5×ULN; For patients with liver metastases, AST and ALT ≤ 5×ULN iii.\tSerum albumin ≥ 28 g/L d.\tCoagulation function: International normalized ratio (INR) and/or activated partial thromboplastin time (APTT) ≤ 1.5× ULN. This applies only to patients who are not on therapeutic anti- coagulation. Patients receiving therapeutic anti-coagulation should be on a stable dose.\n- Patient is willing and able to comply with the visits, treatment protocols, laboratory tests, and other requirements of the study as specified in the schedule.\n- Age ≥ 18 and < 80 years old at the time of enrolment\n- Eastern Cooperative Oncology Organization (ECOG) performance status score of 0 or 1.\n- Expected survival ≥ 6 months at randomization.\n- Histologically and/or cytologically confirmed R/M HNSCC with a primary tumour initially or currently located in the oral cavity, oropharynx, hypopharynx, or larynx.\n- HPV status test results based on tumour tissue samples must be obtained prior to randomization for patients with oropharyngeal cancer.\n- No prior systemic anti-tumour therapy for R/M HNSCC. Note: Patients who have previously received adjuvant/neoadjuvant chemotherapy with curative intent for non-metastatic disease, radiotherapy, or definitive radiotherapy in combination with chemotherapy or cetuximab/EGFR based therapy for locally advanced disease are eligible if disease progression occurs > 6 months after the end of the last treatment.\n- At least one measurable lesion according to RECIST v1.1, or measurable lesion with clear radiographic progression after local therapy, and the lesion must be suitable for repeated accurate measurements.\n- Tumours must be PD-L1 positive (CPS ≥ 1) as confirmed by CE-IVD immunohistochemistry assay based on local assessment with any assay validated for HNSCC in a laboratory compliant with National provisions. The measurement of PD-L1 protein expression can be performed based on archival tissue sample before the diagnosis of R/M tumour or based on tissue sample obtained after the diagnosis of a R/M tumour."}

Exclusion criteria

• {"criterion_text":"- Primary tumour site (any histology) of nasopharynx, nasal cavity, sinuses, salivary glands, thyroid or parathyroid glands, skin, or unknown primary site of tissue origin.\n- Received curative head and neck radiotherapy within 6 months prior to randomization. Palliative local treatment for non-head and neck areas carried out within 3 weeks before randomization; Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymus peptide, tumour necrosis factor, etc.) within 2 weeks prior to randomization, excluding IL-11 for the treatment of thrombocytopenia.\n- Presence of active autoimmune disease requiring systemic therapy (e.g., treatment with disease-modifying drugs, corticosteroids, immunosuppressants) within 2 years prior to randomization. Alternative therapies (e.g., thyroxine, insulin, or those targeting the adrenal glands or pituitary) and physiologic corticosteroid replacement therapy for pituitary insufficiency are not considered systemic treatment.\n- Patients with known active tuberculosis and suspected active tuberculosis need to be excluded by clinical examination; Known active syphilis infection.\n- Severe infection within 4 weeks prior to randomization, including but not limited to comorbidities requiring hospitalization History of immunodeficiency; Those who have history of positive test for HIV antibodies; Current long-term use of systemic\n- sepsis, or severe pneumonia; Active non-severe infection that has received systemic anti-infective therapy within 2 weeks prior to randomization.\n- Patient with malignancies other than HNSCC within 3 years prior to enrolment. Patients with other tumours that have been cured through local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ, are not excluded.\n- Concurrent enrolment in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up period of an interventional study; Received study treatment within 4 weeks prior to randomization.\n- Prior treatment with systemic anti-angiogenic drugs.\n- Previous head and neck re-irradiation for recurrent/metastatic disease\n- Prior immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1/L1 antibody, anti- CTLA-4 antibody, anti-TIGIT antibody, anti-LAG3 antibody, anti-CD47, anti-SIRPα, etc.), immune checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), immune cell therapy, and any other treatment that targets tumour immunity including therapeutic tumour vaccine, and other adjuvant/neoadjuvant anti-PD-1 based therapy.\n- Patients with ulcers on the skin surface related to the current cancer during the screening period, superficial or protruding skin lesions with excessive surface tension and a greater risk of ulceration, or other patients with a greater risk of ulceration as assessed by the investigator. Patients with recent tracheostomy involving the tumour which are at risk of bleeding.\n- Imaging during the screening period shows that the tumour invades/infiltrates the surrounding important organs (such as trachea, oesophagus, and based on investigator assessment of bleeding risk) and/or large blood vessels in the neck (such as subclavian artery, common internal and/or external carotid artery, c, etc.) or if the investigator judges that entering the study might cause a potential risk of bleeding.\n- Presence of brainstem, meningeal metastases, spinal cord metastases or compression, or leptomeningeal disease. 10.\tReceived curative head and neck radiotherapy within 6 months prior to randomization. Palliative local treatment for non-head and neck areas carried out within 3 weeks before randomization; Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymus peptide, tumour necrosis factor, etc.) within 2 weeks prior to randomization, excluding IL-11 for the treatment of thrombocytopenia."}

Primary endpoints

• {"endpoint_text":"- Overall Survival","definition_or_measurement_approach":"Overall Survival (OS) defined as time from randomization to death from any cause; patients alive at analysis are censored at date of last confirmed contact or visit."}

Secondary endpoints

• {"endpoint_text":"- Objective response rate","definition_or_measurement_approach":"ORR defined as the proportion of patients achieving best overall response (complete response CR or partial response PR) as determined by the Blinded Independent Review Committee (BIRC) according to RECIST v1.1; investigator-assessed ORR will also be analysed."}
• {"endpoint_text":"- Progression free survival","definition_or_measurement_approach":"PFS assessed by BIRC based on RECIST v1.1 and defined as time from randomization to first locoregional or distant progression or death from any cause, whichever occurs first."}
• {"endpoint_text":"- Disease control rate","definition_or_measurement_approach":"Disease control rate (DCR) defined as proportion of patients with best overall response CR, PR or SD per RECIST v1.1; Duration of response (DoR) defined as time from first response (CR or PR) to first documented progression or death from any cause."}
• {"endpoint_text":"- safety assessments","definition_or_measurement_approach":"Safety and tolerability assessments as collected per protocol (adverse events, laboratory assessments, vital signs, etc.)."}
• {"endpoint_text":"- pharmacokinetic characteristics","definition_or_measurement_approach":"PK: serum concentrations of ivonescimab and ligufalimab at specified timepoints and exposure-response analyses correlating exposure with selected efficacy and safety parameters."}
• {"endpoint_text":"- Immunogenicity assessment","definition_or_measurement_approach":"Immunogenicity: number and percentage of patients with detectable anti-drug antibodies against ivonescimab (ivo-ADA) and ligufalimab (AK117-ADA)."}

France

Earliest CTIS Part Ii Submission Date

16-10-2025

Latest Decision Or Authorization Date

26-03-2026

Processing Time Days

161

Number Of Sites

39

Number Of Participants

220

Spain

Earliest CTIS Part Ii Submission Date

03-12-2025

Latest Decision Or Authorization Date

18-12-2025

Processing Time Days

15

Number Of Sites

9

Number Of Participants

50

Belgium

Earliest CTIS Part Ii Submission Date

14-11-2025

Latest Decision Or Authorization Date

23-03-2026

Processing Time Days

129

Number Of Sites

1

Number Of Participants

40

Primary sponsor

Full Name

Groupe Oncologie Radiotherapie Tete Cou

Organisation Type

Patient organisation/association

Country Of Registered Address

France

Co-sponsors

• AKESO BIOPHARMA CO., LTD. (Akesobio)